Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
美国以外的医药大麻销售最畅销，增长率达两位数，重点放在德国。
InterCure Ltd. (NASDAQ:INCR) (TASE:INCR) reported its financial and operating results for the six months ended June 30, 2024. The Israeli-based cannabis operator posted revenue of NIS 126 million ($34.58 million), compared to NIS 147 million in the second half of 2023. The company noted that the October 7th terror attack affected the company's revenues in the first half of 2024 due to damages to its southern facility located at Kibbutz Nir Oz.
InterCure Ltd. (纳斯达克：INCR) (特拉维夫证交所：INCR) 报告了截至2024年6月30日的半年财务和运营业绩。这家以色列大麻运营商的营业收入为1.26亿新谢克尔（3458万美元），而2023年下半年为1.47亿新谢克尔。该公司指出，10月7日的恐怖袭击事件对其位于尼尔·奥兹基布斯（Kibbutz Nir Oz）的南方设施造成了损害，影响了2024年上半年的收入。
"Yesterday, we announced the expansion of our strategic partnership with Cookies to the German market, the largest market in Europe, which is experiencing accelerated growth and becoming a key target market for...
“昨天，我们宣布将与维生饼干（Cookies）扩展我们在德国市场...
登录免费看全文
登录/注册